BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38551406)

  • 1.
    Diwanji D; Onishi N; Hathi DK; Lawhn-Heath C; Kornak J; Li W; Guo R; Molina-Vega J; Seo Y; Flavell RR; Heditsian D; Brain S; Esserman LJ; Joe BN; Hylton NM; Jones EF; Ray KM
    Radiol Imaging Cancer; 2024 Mar; 6(2):e230082. PubMed ID: 38551406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multimodal prediction of neoadjuvant treatment outcome by serial FDG PET and MRI in women with locally advanced breast cancer.
    Kazerouni AS; Peterson LM; Jenkins I; Novakova-Jiresova A; Linden HM; Gralow JR; Hockenbery DM; Mankoff DA; Porter PL; Partridge SC; Specht JM
    Breast Cancer Res; 2023 Nov; 25(1):138. PubMed ID: 37946201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between serial dynamic contrast-enhanced MRI and dynamic 18F-FDG PET measures in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer.
    Partridge SC; Vanantwerp RK; Doot RK; Chai X; Kurland BF; Eby PR; Specht JM; Dunnwald LK; Schubert EK; Lehman CD; Mankoff DA
    J Magn Reson Imaging; 2010 Nov; 32(5):1124-31. PubMed ID: 21031518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dedicated breast PET for detecting residual disease after neoadjuvant chemotherapy in operable breast cancer: A prospective cohort study.
    Sasada S; Masumoto N; Goda N; Kajitani K; Emi A; Kadoya T; Okada M
    Eur J Surg Oncol; 2018 Apr; 44(4):444-448. PubMed ID: 29396328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of pathological complete response after neoadjuvant chemotherapy in breast cancer: comparison of diagnostic performances of dedicated breast PET, whole-body PET, and dynamic contrast-enhanced MRI.
    Tokuda Y; Yanagawa M; Fujita Y; Honma K; Tanei T; Shimoda M; Miyake T; Naoi Y; Kim SJ; Shimazu K; Hamada S; Tomiyama N
    Breast Cancer Res Treat; 2021 Jul; 188(1):107-115. PubMed ID: 33730265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between ring-type dedicated breast PET and immune microenvironment in early breast cancer.
    Sasada S; Shiroma N; Goda N; Kajitani K; Emi A; Masumoto N; Kadoya T; Arihiro K; Okada M
    Breast Cancer Res Treat; 2019 Oct; 177(3):651-657. PubMed ID: 31267329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive and prognostic potential of volume-based metabolic variables obtained by a baseline
    Garcia-Vicente AM; Pérez-Beteta J; Amo-Salas M; Molina D; Jimenez-Londoño GA; Soriano-Castrejón AM; Pena Pardo FJ; Martínez-González A
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(2):73-79. PubMed ID: 29102649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early prediction of response to neoadjuvant chemotherapy in breast cancer patients: comparison of single-voxel (1)H-magnetic resonance spectroscopy and (18)F-fluorodeoxyglucose positron emission tomography.
    Cho N; Im SA; Kang KW; Park IA; Song IC; Lee KH; Kim TY; Lee H; Chun IK; Yoon HJ; Moon WK
    Eur Radiol; 2016 Jul; 26(7):2279-90. PubMed ID: 26376886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated
    Cho N; Im SA; Cheon GJ; Park IA; Lee KH; Kim TY; Kim YS; Kwon BR; Lee JM; Suh HY; Suh KJ
    Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):328-339. PubMed ID: 29101445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reliability of
    Jena A; Taneja S; Singh A; Negi P; Sarin R; Das PK; Singhal M
    AJR Am J Roentgenol; 2017 Sep; 209(3):662-670. PubMed ID: 28678576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unexpected Abnormal Uptake in the Breasts at Dedicated Breast PET: Incidentally Detected Small Cancers or Nonmalignant Features?
    Satoh Y; Motosugi U; Omiya Y; Onishi H
    AJR Am J Roentgenol; 2019 Feb; 212(2):443-449. PubMed ID: 30476450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic Tumor Burden Assessed by Dual Time Point [
    Garcia-Vicente AM; Pérez-Beteta J; Pérez-García VM; Molina D; Jiménez-Londoño GA; Soriano-Castrejón A; Martínez-González A
    Mol Imaging Biol; 2017 Aug; 19(4):636-644. PubMed ID: 27981471
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Romine PE; Peterson LM; Kurland BF; Byrd DW; Novakova-Jiresova A; Muzi M; Specht JM; Doot RK; Link JM; Krohn KA; Kinahan PE; Mankoff DA; Linden HM
    Breast Cancer Res; 2021 Aug; 23(1):88. PubMed ID: 34425871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of primary breast cancers using dedicated breast PET and whole-body PET.
    Hathi DK; Li W; Seo Y; Flavell RR; Kornak J; Franc BL; Joe BN; Esserman LJ; Hylton NM; Jones EF
    Sci Rep; 2020 Dec; 10(1):21930. PubMed ID: 33318514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging--prospective assessment.
    Tateishi U; Miyake M; Nagaoka T; Terauchi T; Kubota K; Kinoshita T; Daisaki H; Macapinlac HA
    Radiology; 2012 Apr; 263(1):53-63. PubMed ID: 22438441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic performance of dedicated breast positron emission tomography.
    Hashimoto R; Akashi-Tanaka S; Watanabe C; Masuda H; Taruno K; Takamaru T; Ide Y; Kuwayama T; Kobayashi Y; Takimoto M; Nakamura S
    Breast Cancer; 2022 Nov; 29(6):1013-1021. PubMed ID: 35768684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor metabolism and perfusion in head and neck squamous cell carcinoma: pretreatment multimodality imaging with 1H magnetic resonance spectroscopy, dynamic contrast-enhanced MRI, and [18F]FDG-PET.
    Jansen JF; Schöder H; Lee NY; Stambuk HE; Wang Y; Fury MG; Patel SG; Pfister DG; Shah JP; Koutcher JA; Shukla-Dave A
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):299-307. PubMed ID: 21236594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation Between F-18 Fluorodeoxyglucose Positron Emission Tomography Metabolic Parameters and Dynamic Contrast-Enhanced MRI-Derived Perfusion Data in Patients with Invasive Ductal Breast Carcinoma.
    Kim TH; Yoon JK; Kang DK; Lee SJ; Jung YS; Yim H; An YS
    Ann Surg Oncol; 2015 Nov; 22(12):3866-72. PubMed ID: 25805237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer.
    Groheux D; Sanna A; Majdoub M; de Cremoux P; Giacchetti S; Teixeira L; Espié M; Merlet P; de Roquancourt A; Visvikis D; Hatt M; Resche-Rigon M; Hindié E
    J Nucl Med; 2015 Jun; 56(6):824-31. PubMed ID: 25883123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor metabolism and perfusion ratio assessed by 18F-FDG PET/CT and DCE-MRI in breast cancer patients: Correlation with tumor subtype and histologic prognostic factors.
    An YS; Kang DK; Jung YS; Han S; Kim TH
    Eur J Radiol; 2015 Jul; 84(7):1365-70. PubMed ID: 25886700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.